Illumina Sole Source Reagents and Preventative Maintence FY27

The Illinois Department of Public Health, Office of Disease Control, Division of Laboratories (IDPH-DOL) seeks to award a sole source contract to Illumina, Inc. for whole genome sequencing (WGS) testing reagents, preventative maintenance services, and software solutions for fiscal year 2027. The procurement encompasses WGS reagents for use on MiSeqDX, iSeq 100, and NextSeq 2000 sequencing instruments; preventative maintenance and repair services for five sequencing instruments located at IDPH facilities in Springfield and Chicago; a 12-month BaseSpace Sequence Hub Enterprise Subscription; and 5,000 iCredits for genomic data storage and processing. The contract is designed to support epidemiological disease investigations, newborn screening, and pathogen typing, with annual reagent usage averaging 4,000 to 6,000 samples across programs. The contract period runs from July 1, 2026, through June 30, 2027, with zero renewal options. The sole source procurement is justified based on equipment compatibility, as Illumina, Inc. is the exclusive manufacturer and sole provider of reagents approved for the specified instruments, which are already validated and operational at IDPH-DOL. No bidders' conferences or site visits are documented. The written comment submission and public hearing request deadline is April 17, 2026, at 4:00 p.m.; if interested parties submit written comments or hearing requests, a public hearing is scheduled for April 22, 2026, at 2:00 p.m. via WebEx conference call.

This procurement contains no specific set-aside designations for disadvantaged enterprises or restrictions limiting eligible respondents, as it is structured as a sole source award to Illumina, Inc., the only vendor licensed to manufacture, sell, and service the required sequencing reagents, instruments, and software. IDPH-DOL has an established procurement history with Illumina, Inc. spanning from February 2019 through June 2026, with annual contract values ranging from approximately $87,984 to $1,316,455. The sequencing instruments currently in operation at IDPH facilities are proprietary Illumina equipment, requiring exclusive integration with Illumina-manufactured reagents and service solutions. The estimated total contract value is $644,202.11, which comprises approximately $142,476.55 in instrument service plans, a BaseSpace Sequence Hub Enterprise Subscription, and up to $500,000 allocated for sequencing reagents, consumables, and library preparation kits. IDPH-DOL negotiated pricing with Illumina, Inc. and secured a 5% discount contingent upon the one-year contract commitment. The procurement is funded with federal funds, and the Chief Procurement Officer will consider all written comments and oral testimony before determining whether to approve the sole source award.